Einhorn’s Greenlight Buys Chemours, Blasts Citron Short Call

Updated on
  • Report overestimates legal liability costs, Greenlight says
  • Hedge fund sold Macy’s stake for a loss after guidance cut

Andrew Left: No War of Words With Einhorn Over Chemours

David Einhorn’s Greenlight Capital said it took a stake in Chemours Co., the titanium-dioxide pigment maker spun off from DuPont Co., denouncing a short recommendation from Andrew Left’s Citron Research that said the company had been "designed to fail."

To continue reading this article you must be a Bloomberg Professional Service Subscriber.